ZIMLAB — Zim Laboratories Share News
0.000.00%
Last trade - 00:00- IN₹6.77bn
- IN₹7.60bn
- IN₹3.74bn
Brief: Zim Laboratories Gets Marketing Authorization For Dabigatran Etexilate Capsules In Italy, Europe
Brief: Zim Laboratories March-Quarter Consol Net Profit 37.4 Mln Rupees
Brief: Zim Laboratories To Consider Fund Raising Via Securities Issuance
Brief: Zim Laboratories Gets Marketing Authorization For Tamsulosin + Dutasteride Capsules In Australia
India's Zim Laboratories up after getting marketing authorization for migraine drug in Australia
Brief: Zim Laboratories And Globalpharma Announce Collaboration In GCC Region
Brief: ZIM Laboratories Gets Marketing Authorization For Dimethyl Fumarate Capsules In Portugal
Brief: Zim Laboratories Gets Marketing Authorization For Buprenorphine Sublingual Film In Europe
Brief: Zim Laboratories Invests Upto Euro 1,50,000 In Shares Of Sia Zim Laboratories
Brief: Zim Laboratories Says Upto 3 Million Shares Of Co Held By A Public Shareholder Proposed To Be Sold
Brief: India's Zim Laboratories March-Quarter Consol PAT Rises
Brief: Zim Laboratories Says Not Received Any Show-Cause Notice Or Any Notice To Stop Manufacturing From Any Drug Authority